Conjugated estrogens vaginal - Teva

Drug Profile

Conjugated estrogens vaginal - Teva

Alternative Names: Bijuva; SCE A

Latest Information Update: 15 Mar 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Barr Laboratories
  • Developer Teva Pharmaceutical Industries
  • Class Estradiol congeners; Hormonal replacements; Osteoporosis therapies
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Atrophic vaginitis

Most Recent Events

  • 01 Dec 2008 Registered for Vaginal atrophy in USA (Vaginal)
  • 26 Apr 2005 Duramed Pharmaceuticals has received a non-approvable letter from the US FDA for Bijuva™ in Vaginal atrophy
  • 04 Nov 2004 Preregistration for Vaginal atrophy in USA (Vaginal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top